EyePoint (EYPT) FCF Margin (2010 - 2026)
EyePoint (EYPT) posted FCF Margin of 11587.36% for Q1 2026, down 5.28% sequentially from 11006.61% in Q4 2025, and down 1136994.0% YoY from N/an in Q1 2025.
EyePoint (EYPT) FCF Margin (2010 - 2026) Analysis & Trends
EyePoint has reported FCF Margin for 17 years, with the latest figure at 11587.36% in Q1 2026.
- Quarterly FCF Margin fell 1136994.0% year-over-year to 11587.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3557.11% (down 328636.0% YoY) and the FY2025 annual result came in at 775.84%, down 47478.0% from the prior year.
- FCF Margin retreated to 11587.36% in Q1 2026 per EYPT's latest filing, from 11006.61% in the prior quarter.
- Over five years, FCF Margin peaked at 631.6% in Q2 2023 and troughed at 11587.36% in Q1 2026.
- A 5-year average of 1872.99% and a median of 218.5% in 2022 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2026: FCF Margin jumped 79884 bps in 2023, then slumped 1136994 bps in 2026.
- Over 5 years, FCF Margin stood at 125.06% in 2022, then tumbled by 32 bps to 164.73% in 2023, then plunged by 96 bps to 323.43% in 2024, then plunged by 3303 bps to 11006.61% in 2025, then dropped by 5 bps to 11587.36% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 11587.36%, 11006.61%, and 6146.79% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -12,310.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12,310.06% |
| Mar 31, 2026 | -11,587.36% |
| Dec 31, 2025 | -11,006.61% |
| Sep 30, 2025 | -6,146.79% |
| Jun 30, 2025 | -1,173.95% |
| Mar 31, 2025 | -217.41% |
| Dec 31, 2024 | -323.43% |
| Sep 30, 2024 | -391.77% |
| Jun 30, 2024 | -209.59% |
| Mar 31, 2024 | -271.36% |
| Dec 31, 2023 | -164.73% |
| Sep 30, 2023 | -100.01% |
| Jun 30, 2023 | 631.60% |
| Mar 31, 2023 | -225.42% |
| Dec 31, 2022 | -125.06% |
| Sep 30, 2022 | -143.17% |
| Jun 30, 2022 | -167.24% |
| Mar 31, 2022 | -218.50% |
| Dec 31, 2021 | -144.39% |
| Sep 30, 2021 | -87.40% |